268 related articles for article (PubMed ID: 32607584)
1. Engineering monoclonal antibody-based contraception and multipurpose prevention technologies†.
Anderson DJ; Politch JA; Cone RA; Zeitlin L; Lai SK; Santangelo PJ; Moench TR; Whaley KJ
Biol Reprod; 2020 Aug; 103(2):275-285. PubMed ID: 32607584
[TBL] [Abstract][Full Text] [Related]
2. Safety, acceptability, and pharmacokinetics of a monoclonal antibody-based vaginal multipurpose prevention film (MB66): A Phase I randomized trial.
Politch JA; Cu-Uvin S; Moench TR; Tashima KT; Marathe JG; Guthrie KM; Cabral H; Nyhuis T; Brennan M; Zeitlin L; Spiegel HML; Mayer KH; Whaley KJ; Anderson DJ
PLoS Med; 2021 Feb; 18(2):e1003495. PubMed ID: 33534791
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women.
Baldeon-Vaca G; Marathe JG; Politch JA; Mausser E; Pudney J; Doud J; Nador E; Zeitlin L; Pauly M; Moench TR; Brennan M; Whaley KJ; Anderson DJ
EBioMedicine; 2021 Jul; 69():103478. PubMed ID: 34256345
[TBL] [Abstract][Full Text] [Related]
4. Hexavalent sperm-binding IgG antibody released from vaginal film for development of potent on-demand nonhormonal female contraception.
Shrestha B; Vincent K; Schaefer A; Zhu Y; Vargas G; Motamedi M; Swope K; Morton J; Simpson C; Pham H; Brennan MB; Pauly MH; Zeitlin L; Bratcher B; Whaley KJ; Moench TR; Lai SK
Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34815336
[TBL] [Abstract][Full Text] [Related]
5. Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.
Dohadwala S; Geib MT; Politch JA; Anderson DJ
Front Reprod Health; 2023; 5():1337479. PubMed ID: 38264184
[TBL] [Abstract][Full Text] [Related]
6. Canadian Contraception Consensus (Part 1 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
[TBL] [Abstract][Full Text] [Related]
7. Multipurpose prevention technologies for reproductive and sexual health.
Stone A
Reprod Health Matters; 2014 Nov; 22(44):213-7. PubMed ID: 25555778
[TBL] [Abstract][Full Text] [Related]
8. Canadian Contraception Consensus (Part 2 of 4).
Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
[TBL] [Abstract][Full Text] [Related]
9. Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies.
Thurman AR; Clark MR; Doncel GF
Infect Dis Obstet Gynecol; 2011; 2011():1-10. PubMed ID: 21836811
[TBL] [Abstract][Full Text] [Related]
10. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.
Friend DR; Doncel GF
Antiviral Res; 2010 Dec; 88 Suppl 1():S47-54. PubMed ID: 21109068
[TBL] [Abstract][Full Text] [Related]
11. LALAPG variant of the Human Contraception Antibody (HCA) reduces Fc-mediated effector functions while maintaining sperm agglutination activity.
Mausser E; Nador E; Politch JA; Pauly MR; Marathe JG; Moench TR; Zeitlin L; Whaley KJ; Anderson DJ
PLoS One; 2023; 18(3):e0282147. PubMed ID: 36996137
[TBL] [Abstract][Full Text] [Related]
12. Vaginal multipurpose prevention technologies: promising approaches for enhancing women's sexual and reproductive health.
Fernandes T; Baxi K; Sawarkar S; Sarmento B; das Neves J
Expert Opin Drug Deliv; 2020 Mar; 17(3):379-393. PubMed ID: 32036727
[No Abstract] [Full Text] [Related]
13. Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.
Hynes JS; Sheth AN; Lathrop E; Sales JM; Haddad LB
J Womens Health (Larchmt); 2019 May; 28(5):665-672. PubMed ID: 30615569
[No Abstract] [Full Text] [Related]
14. Passive immunization of the human vagina.
Anderson DJ
Hum Vaccin Immunother; 2022 Apr; 18(2):1965423. PubMed ID: 34473605
[TBL] [Abstract][Full Text] [Related]
15. Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women.
Seidman D; Hemmerling A; Smith-McCune K
Semin Reprod Med; 2016 May; 34(3):159-67. PubMed ID: 26956691
[TBL] [Abstract][Full Text] [Related]
16. A Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products.
Dohadwala S; Politch JA; Barmine JH; Anderson DJ
Open Access J Contracept; 2023; 14():83-94. PubMed ID: 37332341
[TBL] [Abstract][Full Text] [Related]
17. Reproductive failure and antisperm-antibody production among prostitutes.
Bahraminejad R; Kadanali S; Erten O; Bahar H
Acta Obstet Gynecol Scand; 1991; 70(6):483-5. PubMed ID: 1763614
[TBL] [Abstract][Full Text] [Related]
18. Lessons from reproductive health to inform multipurpose prevention technologies: don't reinvent the wheel.
Brady M; Manning J
Antiviral Res; 2013 Dec; 100 Suppl():S25-31. PubMed ID: 24188700
[TBL] [Abstract][Full Text] [Related]
19. A strategic action framework for multipurpose prevention technologies combining contraceptive hormones and antiretroviral drugs to prevent pregnancy and HIV.
Young Holt B; Dellplain L; Creinin MD; Peine KJ; Romano J; Hemmerling A
Eur J Contracept Reprod Health Care; 2018 Oct; 23(5):326-334. PubMed ID: 30247084
[TBL] [Abstract][Full Text] [Related]
20. Prioritizing multipurpose prevention technology development and investments using a target product profile.
Romano J; Manning J; Hemmerling A; McGrory E; Holt BY
Antiviral Res; 2013 Dec; 100 Suppl():S32-8. PubMed ID: 24188707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
